The 17th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma will provide a unique opportunity for medical oncologists, hematologists, and other health care professionals to learn from and to interact with international leaders in the field of hematologic malignancies in order to increase knowledge, apply new data to practice, and improve patient outcomes.

Target Audience

This CME activity is directed toward medical oncologists and hematologists interested in the treatment of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

• Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of hematologic malignancies, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
• Integrate genomic and molecular biomarkers when appropriate into risk assessment and treatment selection for patients with hematologic malignancies
• Compare efficacy and safety data supporting treatment options for lymphoma (including indolent and aggressive B cell lymphomas, Hodgkin lymphoma, and T cell lymphomas) in order to optimize outcomes for individual patients
• Individualize therapy for patient with newly diagnosed and relapsed/refractory multiple myeloma based on assessment of transplant eligibility, patient and tumor characteristics, and risk/benefit profiles of available regimens
• Discuss strategies for the first-line treatment of chronic-phase chronic myeloid leukemia, as well as monitoring guidelines and options for patients in accelerated- or blast-phase
• Evaluate the efficacy and safety of standard and emerging treatment approaches for patients with acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders in order to personalize therapy for individual patients.
• Review recent advances in treatment options for chronic lymphocytic leukemia, including the use of prognostic factors, to optimize outcomes.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. PER additionally requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI. All relevant financial relationships with any commercial interests are disclosed to participants prior to the beginning of PER’s CME activities. PER has identified and resolved all COI prior to the start of this activity using a multi-step process.

Off-Label Disclosure and Disclaimer

This CME activity will contain discussions about off-label/unapproved uses of drugs including but not limited to brentuximab vedotin, carfilzomib, pomalidomide, doxorubicin, dexamethasone, bortezomib, bendamustine, melphalan, lenalidomide, delanzomib, ibrutinib, idelalisib, rituximab for ITP, romiplostim and eltrombopag for pediatric ITP, E5501 (avatrombopag maleate) for ITP, ABT‑199, IPI-145, SCDT 2980s, ofatumumab, aurora kinase inhibitors, GS-1101, PCYC-32765, IP2101, ibritumomab tiuxetan, interferon in MPNs, rigosertib, clofarabine for MDS, ponatinib, blinatumomab, azacitidine, decitabine and clofarbine.
 
For additional information about approved uses, including approved indications, contraindications, and warnings, participants are advised to consult prescribing information for all products discussed or consult the Physicians’ Desk Reference. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
 
Disclaimer
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this CME activity.

Faculty and Staff Disclosures

The following individuals have relevant financial relationships with commercial interests to disclose:

Ranjana Advani, MD – Grant/Research Support – Allos Therapeutics, Seattle Genetics; Nancy Bartlett, MD – Paid Travel Expenses (ASCO Poster Presentation) – Seattle Genetics; James Berenson, MD – Grant/Research Support – Amgen, Novartis, Medtronic, Onyx, Millennium; Consultant: Onyx, Millennium, Amgen, Medtronic; Speaker’s Bureau – Onyx, Millenium, Amgen, Medtronic; Donald Berry PhD – Consultant – Berry Consultants, LLC; Stock/Shareholder – Co-owner of Berry Consultants, LLC; Jennifer Brown, MD, PhD – Grant/Research Support – Genzyme (now sanofi-aventis); Consultant – Genentech, Emergent, sanofi-aventis, Celgene, Onyx; James Bussel, MD – Grant/Research Support – Amgen, Cangene, GlaxoSmithKline, Genzyme, IgG of America, Immunomedics, Ligand, Eisai Inc, Shionogi, Sysmex; Consultant/Ad Board – Amgen, GlaxoSmithKline, Ligand, Shionogi, Symphogen, Eisai, Inc; Stock/Shareholder – Amgen, GlaxoSmithKline;  Bruce Cheson, MD – Consultant – Genentech, Celgene; Nicholas Chiorazzi, MD – Grant/Research Support: Pharmacyclics; Stock/Shareholder – Kinemed, Inc.; Daniel DeAngelo, MD, PhD – Consultant – Amgen; Harry Erba, MD – Grant/Research Support – Novartis, , Celator, GenzymeMillennium; Speaker’s Bureau – Celgene, Novartis, Incyte; Alessandra Ferrajoli, MD – Grant/Research Support – Celgene, GlaxoSmithKline; Other Support (Advisory Board) – Celgene, Pharmacyclics; Jonathan Friedberg, MD – Consultant – Genentech, Bayer, Seattle Genetics; Other Support (Data and Safety Monitoring): Lilly; Randy Gascoyne, MD, FRCPC – Grant/Research Support – Seattle Genetics, Roche Canada; Consultant – Seattle Genetics, Celgene, Janssen, Genentech, Roche; Speaker’s Bureau – Seattle Genetics; Andre Goy, MD – Clinical Trial Support Through Institutions; Speaker’s Bureau – Millennium; Advisory Board – Millennium, Celgene, Pharmacyclics, Johnson & Johnson, Seattle Genetics, Pfizer; Paul Hamlin, MD – Grant/Research Support – Spectrum, GlaxoSmithKline, Pfizer, Seattle Genetics; Consultant – Genentech, Gilead, Spectrum; Steven Horwitz, MD – Grant/Research Support – Celgene, Allos, Seattle Genetics, Infinity, Kyowa, Millennium; Consultant – Celgene, Allos, Seattle Genetics, Bristol Myers Squibb, Genzyme, Kyowa, Johnson & Johnson, Janssen, Millennium; Sundar Jagannath, MD – Consultant – Merck, Celgene, Millennium; Thomas Kipps, MD, PhD – Grant/Research Support – Abbott, Celgene, Genentech, Pharmacyclics, AstraZeneca, Amgen, Medimmude, Gilead; Consultant – Onyx; Stock/Shareholder – Eclipse Tx, Ingenica; Michael Mauro, MD – Grant/Research Support – Novartis, Bristol Myers Squibb, Ariad; Consultant – Novartis, Bristol Myers Squibb, Ariad, Pfizer; Ruben Mesa, MD, FACP – Research Support – Inyte, Celgene, Gilead, Infinity, Lilly, NS Pharma; Ari Melnick, MD – Grant/Research Support – NCI, Leukemia and Lymphoma Society; Consultant – Celgene; Speaker’s Bureau – Genentech; Craig Moskowitz, MD – Grant/Research Support – Seattle Genetics, Roche, GlaxoSmithKline, Plexxikon, Cephalon; Consultant – Seattle Genetics, Roche, GlaxoSmithKline; Nikhil Munshi, MD – Consultant – Celgene, Merck, Millenium, Onyx; Daniel Persky, MD – Grant/Research Support – Merck; Lauren Pinter-Brown, MD, FACP – Consultant – Spectrum; Pierluigi Porcu, MD – Grant/Research Support – Millennium; Consultant – Hospira, Elorac; Charles Schiffer, MD – Grant/Research Support – Ariad, Celgene, Ambit, Bristol Myers Squibb; Consultant – Eisai, Teva, Celgene, Novartis, Bristol Myers Squibb; Richard Silver, MD – Grant/Research Support – Merck; Clinical Trial Investigator – Interferon in treatment in early phase myleofibrosis; David Steensma, MD – Consultant – Amgen, Array, Biopharma, Boehringer Ingelheim, Celgene; Richard Stone, MD – Grant/Research Support – Novartis; Consultant – Teva, Seattle Genetics, Amgen; Other Support – Sunesis (OSMB), Amgen (Steering Committee); Moshe Talpaz, MD – Grant/Research Support – Novartis, Ariad, Bristol Myers Squibb, sanofi-aventis, Incyte; Consultant – Novartis, Ariad, Bristol Myers Squibb, Teva; Speaker’s Bureau – Novartis, Ariad; William Wierda, MD, PhD – Grant/Research Support – Abbott, GlaxoSmithKline, Genentech/Roche; Consultant – Celgene, Genentech/Roche, Merck, sanofi-aventis; Speaker’s Bureau – Celgene, GlaxoSmithKline, Genentech/Roche; Anas Younes, MD – Grant/Research Support – Seattle Genetics, Millennium, Johnson & Johnson, Gilead, Novartis; Consultant – Seattle Genetics, Millennium, ISIS, Novartis; Andrew Zelenetz, MD – Research – Roche, GlaxoSmithKline, Genentech; Consulting – Seattle Genetics, sanofi-aventis USA, GlaxoSmithKline, Gilead, Cephalon, Celgene; Other – Scientific Advisor – Cancer Genetics
 
The following individuals have no relevant financial relationships with commercial interests to disclose: Patrick Brown, MD; Eric Feldman, MD; Virginia Klimek, MD, Ola Landgren, MD, PhD; Ross Levine, MD; Joachim Yahalom, MD
 
Physicians’ Education Resource®, LLC Planning Staff – Ann C. Lichti, CCMEP, Tristan Nelsen, MNM, CMP and Susan Peck, PhD.